product summary
company name :
Cell Signaling Technology
product type :
antibody
product name :
PLK1 Antibody
catalog :
4535
clonality :
polyclonal
host :
rabbit
conjugate :
nonconjugated
reactivity :
human, mouse, rat
application :
western blot
citations: 10
Published Application/Species/Sample/DilutionReference
  • western blot; mouse; 1:2000; loading ...; fig s6a
Izumi T, Imai J, Yamamoto J, Kawana Y, Endo A, Sugawara H, et al. Vagus-macrophage-hepatocyte link promotes post-injury liver regeneration and whole-body survival through hepatic FoxM1 activation. Nat Commun. 2018;9:5300 pubmed publisher
  • western blot; human; 1:1000; loading ...; fig 1b
Schwermer M, Dreesmann S, Eggert A, Althoff K, Steenpass L, Schramm A, et al. Pharmaceutically inhibiting polo-like kinase 1 exerts a broad anti-tumour activity in retinoblastoma cell lines. Clin Exp Ophthalmol. 2017;45:288-296 pubmed publisher
  • western blot; human; loading ...; fig 4b
McCloy R, Parker B, Rogers S, Chaudhuri R, Gayevskiy V, Hoffman N, et al. Global Phosphoproteomic Mapping of Early Mitotic Exit in Human Cells Identifies Novel Substrate Dephosphorylation Motifs. Mol Cell Proteomics. 2015;14:2194-212 pubmed publisher
Amani V, Prince E, Alimova I, Balakrishnan I, Birks D, Donson A, et al. Polo-like Kinase 1 as a potential therapeutic target in Diffuse Intrinsic Pontine Glioma. BMC Cancer. 2016;16:647 pubmed publisher
Rodgers L, O Hainmhire E, Young A, Burdette J. Loss of PAX8 in high-grade serous ovarian cancer reduces cell survival despite unique modes of action in the fallopian tube and ovarian surface epithelium. Oncotarget. 2016;7:32785-95 pubmed publisher
Wang N, Li Z, Zhao H, Tao Y, Xu L, Lu J, et al. Molecular targeting of the oncoprotein PLK1 in pediatric acute myeloid leukemia: RO3280, a novel PLK1 inhibitor, induces apoptosis in leukemia cells. Int J Mol Sci. 2015;16:1266-92 pubmed publisher
McCloy R, Rogers S, Caldon C, Lorca T, Castro A, Burgess A. Partial inhibition of Cdk1 in G 2 phase overrides the SAC and decouples mitotic events. Cell Cycle. 2014;13:1400-12 pubmed publisher
Danovi D, Folarin A, Gogolok S, Ender C, Elbatsh A, Engström P, et al. A high-content small molecule screen identifies sensitivity of glioblastoma stem cells to inhibition of polo-like kinase 1. PLoS ONE. 2013;8:e77053 pubmed publisher
Niu R, Yoshida M, Ling F. Increases in mitochondrial DNA content and 4977-bp deletion upon ATM/Chk2 checkpoint activation in HeLa cells. PLoS ONE. 2012;7:e40572 pubmed publisher
Harris P, Venkataraman S, Alimova I, Birks D, Donson A, Knipstein J, et al. Polo-like kinase 1 (PLK1) inhibition suppresses cell growth and enhances radiation sensitivity in medulloblastoma cells. BMC Cancer. 2012;12:80 pubmed publisher
product information
SKU :
4535S
Product-Name :
PLK1 Antibody
Size :
200 ul
Price-(USD) :
235 USD
Species-x-Reactivity :
H, M, R, Mk, (Pg)
Applications :
Western blot
Product-Category :
Cell Cycle / Checkpoint Control
Shipping-Temp :
AMBIENT
Storage-Temp :
-20°C
Product-Type :
Polyclonal Antibody
MW :
62
Host :
Rabbit
Target :
PLK1
Primary-Protein :
PLK1
Alt-Names :
PLK,PLK-1,PLK1,Polo-like kinase 1,STPK13,Serine/threonine-protein kinase 13,Serine/threonine-protein kinase PLK1,cell cycle regulated protein kinase,polo (Drosophia)-like kinase,polo like kinase,polo-like kinase 1 (Drosophila)
company information
Cell Signaling Technology
3 Trask Lane
Danvers, MA 01923
info@cellsignal.com
https://www.cellsignal.com
8776162355
headquarters: USA
Established in Beverly, MA in 1999, Cell Signaling Technology (CST) is a privately-owned company with over 400 employees worldwide. We are dedicated to providing innovative research tools that are used to help define mechanisms underlying cell function and disease. Since its inception, CST has become the world leader in the production of the highest quality activation-state and total protein antibodies utilized to expand knowledge of cell signaling pathways. Our mission is to deliver the world's highest quality research tools that accelerate progress in biological research and personalized medicine.